Prazolok™ ER

Prazosin
Alpha Receptor Blocker (Cardiovascular Preparations)

Indication:

Hypertension (Primary and Secondary Hypertension).

Dosage & Administration:

Prazosin Extended Release (ER) Tablet administration in Hypertension: Prazosin extended release tablet therapy must be initiated at 2.5 mg once daily. The 5 mg dosage form is not for initial dosing. Dosage should be increased slowly, in general over a 7 to 14 day period, depending on the response to each dose level. Maximum dose: Dosage may be increased to 20 mg once daily.
Prazosin Extended Release (ER) Tablet administration in Patients with moderate to severe grades of renal impairment: Evidence to date shows that Prazosin does not further compromise renal function when used in patients with renal impairment. As some patients in this category have responded to small doses of Prazosin, it is recommended that therapy be initiated at 2.5 mg daily and that dosage increases be instituted cautiously.
Patients controlled with Prazosin Immediate Release (IR) tablets alone or in combination with other antihypertensive medications may be switched to Prazosin ER Tablets at the equivalent or nearest higher total daily dose (e.g. Prazosin IR Tablets 4 mg daily equivalent to Prazosin ER Tablet 5 mg once daily).

Preparation:

Prazolok^™ ER 2.5: Each box contains 30 tablets in blister pack.
Prazolok^™ ER 5: Each box contains 30 tablets in blister pack.